Peptipedia
Growth HormonePreclinicalClinical Trials

GHRP-6

Also known as Growth Hormone Releasing Peptide 6, SKF-110679

One of the first synthetic GH secretagogues developed. Strongly stimulates GH release and significantly increases appetite.

Preclinical/Investigational - Extensive research history
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

100-300 mcg, 2-3x daily

Frequency

2-3 times daily

Duration

8-12 weeks

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 100-300 mcg, 2-3x daily via Subcutaneous injection (fasted), 2-3 times daily. Dose range: 100-300 mcg per dose. Duration: 8-12 weeks.

Timing & Administration

Administer via Subcutaneous injection (fasted). Frequency: 2-3 times daily.

Mechanism of Action

Binds to ghrelin receptors (GHSR-1a) in the hypothalamus and pituitary, triggering strong GH release. Activates the hunger-signaling pathway. Stimulates cortisol and prolactin more than newer GHRPs.

Research Summary

Evidence level: clinical trials. Clinical status: Preclinical/Investigational - Extensive research history.

Side Effects & Safety

Important Warnings

  • Elevated cortisol and prolactin compared to newer GHRPs
Significant hunger increase
water retention
elevated cortisol and prolactin
flushing
nausea
headache
potential histamine release

References

No references available.

Related Peptides

Browse all →
IpamorelinGrowth Hormone

A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.

View profile
CJC-1295Growth Hormone

A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary.

View profile
TesamorelinGrowth Hormone

An FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.

View profile